Why we're expanding into Transplant & Cellular Therapies

What are Transplant & Cellular Therapies?

Transplant and cellular therapies (TCT) are fast-evolving, life-saving treatments using a patient’s own cells—or donor cells. They are mainly indicated in malignant diseases like leukemia, lymphoma, and multiple myeloma.

These treatments are booming.

Some of them, like “CAR-T therapy, have been considered a major breakthrough in cancer immunotherapy, owing to treatment response rates observed in even heavily pretreated patients." (Source: JCO Oncology Practice, 2023. "Operationalizing CAR-T Therapy in Clinical Practice: Challenges and Opportunities.")

But so is the complexity of delivering them.

⚡️ Coordinating care across multiple departments.

⚡️ Manually scheduling through spreadsheets

⚡️ Adjusting operations to frequent changes in care trajectories

⚡️ No visibility into downstream impact of operational decisions

The consequences:

👴 For patients: Limited access to live-saving therapies.

👩‍⚕️ For staff: Stress and administrative burden leading to burnout.

🏥 For centers: Wasted capacity, affecting financial performance and ability to deliver quality care.

So we’ve decided to bring what we do best:

✅ Smart scheduling automation

✅ Capacity optimization management

✅ Real-time orchestration across departments

✅ Ops intelligence and predictive analytics

Because

🌍 We dream of a healthcare system where no resources are wasted — and where every patient has equitable access to care, no matter the disease;

🔁 The challenges we tackle go beyond a single service line — they’re part of delivering high-quality, patient-centered, integrated care;

💫 And because from day one, our platform was designed to scale across departments, locations... and diseases.

GrayOS orchestrates and optimizes operations...

The numerous silos of care orchestated by GrayOS

...across and within silos of care